(Q33371900)

26 July 2017

title

Phase II study of single-agent bortezomib for the treatment of patients with fludarabine-refractory B-cell chronic lymphocytic leukemia (English)

1 reference

B-cell chronic lymphocytic leukemia

26 July 2017

0 references

1 reference

1 reference

Ian W Flinn

5

0 references

Stefan Faderl

series ordinal

1

object named as

Stefan Faderl

1 reference

26 July 2017

6

Susan O'Brien

1 reference

26 July 2017

9

Michael J Keating

1 reference

26 July 2017

4

John C Byrd

1 reference

26 July 2017

3

John Gribben

1 reference

26 July 2017

2

Kanti Rai

1 reference

26 July 2017

Shihong Sheng

7

1 reference

26 July 2017

Dixie-Lee Esseltine

series ordinal

8

1 reference

26 July 2017

language of work or name

English

0 references

publication date

1 September 2006

1 reference

26 July 2017

1 reference

26 July 2017

volume

107

1 reference

26 July 2017

issue

5

1 reference

26 July 2017

page(s)

916-924

1 reference

The proteasome inhibitor lactacystin induces apoptosis and sensitizes chemo- and radioresistant human chronic lymphocytic leukaemia lymphocytes to TNF-alpha-initiated apoptosis

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22097

Chronic Lymphocytic Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22097

7 January 2021

Chronic lymphocytic leukemia incidence is substantially higher than estimated from tumor registry data

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22097

7 January 2021

Guidelines on the diagnosis and management of chronic lymphocytic leukaemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22097

7 January 2021

Current approach to diagnosis and management of chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22097

7 January 2021

Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22097

7 January 2021

Advances in chemotherapy for chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22097

7 January 2021

Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22097

7 January 2021

Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22097

7 January 2021

Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22097

7 January 2021

Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22097

7 January 2021

Efficacy and safety of fludarabine and cyclophosphamide combined therapy in patients with refractory/recurrent B-cell chronic lymphocytic leukaemia (B-CLL)-Polish multicentre study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22097

7 January 2021

Fludarabine, cyclophosphamide and mitoxantrone in relapsed or refractory chronic lymphocytic leukemia and low grade non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22097

7 January 2021

Subcutaneous CAMPATH-1H in fludarabine-resistant/relapsed chronic lymphocytic and B-prolymphocytic leukaemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22097

7 January 2021

Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22097

7 January 2021

Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22097

7 January 2021

Remission induction using alemtuzumab can permit chemotherapy-refractory chronic lymphocytic leukemia (CLL) patients to undergo allogeneic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22097

7 January 2021

Filgrastim and alemtuzumab (Campath-1H) for refractory chronic lymphocytic leukemia.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22097

7 January 2021

Treatment of relapsed chronic lymphocytic leukemia by 72-hour continuous infusion or 1-hour bolus infusion of flavopiridol: results from Cancer and Leukemia Group B study 19805.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22097

7 January 2021

Flavopiridol administered as a 24-hour continuous infusion in chronic lymphocytic leukemia lacks clinical activity

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22097

7 January 2021

Lack of effect of 2-chlorodeoxyadenosine therapy in patients with chronic lymphocytic leukemia refractory to fludarabine therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22097

7 January 2021

Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22097

7 January 2021

Development of the proteasome inhibitor Velcade (Bortezomib).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22097

7 January 2021

The ubiquitin-proteasome pathway and proteasome inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22097

7 January 2021

Potential for proteasome inhibition in the treatment of cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22097

7 January 2021

Proteasome inhibition: a new strategy in cancer treatment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22097

7 January 2021

Targeting BCL-2 overexpression in various human malignancies through NF-kappaB inhibition by the proteasome inhibitor bortezomib

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22097

7 January 2021

Increased sensitivity of CLL-derived lymphocytes to apoptotic death activation by the proteasome-specific inhibitor lactacystin

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22097

7 January 2021

Proteasome inhibitor-induced apoptosis of B-chronic lymphocytic leukaemia cells involves cytochrome c release and caspase activation, accompanied by formation of an approximately 700 kDa Apaf-1 containing apoptosome complex

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22097

7 January 2021

Cycling B-CLL cells are highly susceptible to inhibition of the proteasome: involvement of p27, early D-type cyclins, Bax, and caspase-dependent and -independent pathways

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22097

7 January 2021

Treatment of human chronic lymphocytic leukemia cells with the proteasome inhibitor bortezomib promotes apoptosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22097

7 January 2021

In vitro cytotoxic effect of proteasome inhibitor bortezomib in combination with purine nucleoside analogues on chronic lymphocytic leukaemia cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22097

7 January 2021

Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22097

7 January 2021

A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22097

7 January 2021

Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22097

7 January 2021

A phase 2 study of bortezomib in relapsed, refractory myeloma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22097

7 January 2021

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22097

7 January 2021

Phase I study of the proteasome inhibitor bortezomib in pediatric patients with refractory solid tumors: a Children's Oncology Group study (ADVL0015).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22097

7 January 2021

Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22097

7 January 2021

Proteasome inhibition with bortezomib (PS-341): a phase I study with pharmacodynamic end points using a day 1 and day 4 schedule in a 14-day cycle

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22097

7 January 2021

Emerging information on the use of rituximab in chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22097

7 January 2021

Rituximab dose-escalation trial in chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22097

7 January 2021

Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22097

7 January 2021

Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22097

7 January 2021

Identifiers

DOI

10.1002/CNCR.22097

1 reference

26 July 2017

1 reference